Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMonica TaniGMGabriel ManSPSheel Patel

Discussion

Loading...

Member takes

Overview

Initial results from a phase 1/1b trial indicate 100% response rate in treatment-naive chronic lymphocytic leukemia patients, highlighting the potential of combination therapy.

Key Points

  • Combination therapy achieved 100% overall response rate in patients with chronic lymphocytic leukemia.
  • The most common adverse event was neutropenia, occurring in 80% of patients.
  • Trial involved patients receiving zanubrutinib, obinutuzumab, and sonrotoclax, with effective monitoring of minimal residual disease.
  • Indicates significant potential for this combination therapy as a treatment option for chronic lymphocytic leukemia.

Cite This Study

Tani et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86fhttps://doi.org/10.1182/blood-2025-3890
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study2025 · 1 citations
  2. 2MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  3. 3Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study2025 · 1 citations
  4. 4Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025
  5. 5Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations